الدكتور حيدر القريشي من الأطباء المتميزين العراقيين المعاصرين

Scientific bibliography

الدكتور حيدر مطير خليل القريشي من مواليد العراق 26\3\1972 متزوج وله ثلاث بنات…يقيم في العراق ويعم كأستاذ تدريسي   في كليه الطب الجامعه المستنصريه .

بكالوريوس بالطب والجراحة العامه  (الأول على الدفعه )1996 , حصل على افضل طالب في الجامعة المستنصريه عام 1995 , حصل على المرتبه الثالثه للطلبه الأوئل لخريجي كليات الطب في العراق ,     ماجستير ودكتوراه في الادويه السريري, عضو كلية الاطباء الملكية (أدنبره) MRCP , زميل كلية الاطباء الملكية ادنبره (FRCP) , عضو الجمعيه البريطانيه للروماتيزم (BSR), عضو الجمعيه الأمريكيه للعلوم الطبية ((AASCIT, عضو جمعيه أطباء العراق العالمية((IIAS.

البريد الاكتروني : Hayderm36@yahoo.com

وظاىف شغلتها (1996-2022)

طبيب دوري في مدينة الطب (1996-1998)

معيد في كلية الطب الجامعه المستنصرية (1998-2005)

تدريسي في كلية الطب الجامعه المستنصرية (2005-2022)

اشراف على اكثر من 20 طالب دراسات عليا

مسؤل لجنة الأشراف والتقويم العلمي

عضو لجنه الترقيات العلميه

النشاط العلمي

عضو تحرير في مجله طب المستنصريه وكذللك في المجلات العالميه

نشر أكثر من 350 بحث ضمن مستوعبات سكوبس, ويب ساينس والبب ميد (https://www.researchgate.net/profile/Hayder-Al-Kuraishy

في نهايه عام 2019 ومنذ بدأ جائحة كورونا قام الاستاذ الدكتور حيدر القريشي بتكوين فريق طبي بحثي علمي شمل الكثير من الباحثين والعلماء من مختلف انحاء العالم شملت مصر, فرنسا , البرتغال, امريكا, المملكة المتحدة , اسبانيا , كوريا, الهند ,غانا , استراليا , النمسا والعديد من الدول الأجنبية.

على هذا الصعيد تم نشر 30 بحث في عام 2020 و 41 في عام 2021 واكثر من60 بحث عام 2022 ومن خلال ذللك تم أختيار الاستاذ الدكتور حيدر القريشي من قبل وزاره التعليم العالي والبحث العلمي  كثاني باحث عربي بالعالم بالنشر حول جائحة كورونا .  على هذا المجال تم دعوة الاستاذ الدكتور حيدر القريشي في الكثير من المؤتمرات العلميه خارج العراق. تم تكريمه كافضل باحث في كلية الطب الجامعه المستنصرية.

كذللك قام الاستاذ الدكتور حيدر القريشي بنشر الكثير من البحوث العلمية في الكثير من الأختصات حول الجلطه القلبية , الجلطة الدماغيه , داء السكري , السمنه وضغط الدم. الأن هو احد المقيمين للبحوث العلميه الرصينية للكثير من دور النشر مثل frontiers, MDPI, Wiely, .

تم استضافتة في العديد من القنوات الفضائية للتحدث عن الامور الطبيه .

البحوث المنشورة فقط في عام 2022

Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, De Waard M, Al-Hamash SM, Jean-Marc S, Negm WA, Batiha GE. The role of berberine in Covid-19: potential adjunct therapy. Inflammopharmacology. 2022 Oct 2:1-4.

Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022 Aug 31:1-0.

Babalghith AO, Al-Kuraishy HM, Al-Gareeb AI, De Waard M, Sabatier JM, Saad HM, Batiha GE. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not?. Diagnostics. 2022 Aug 24;12(9):2051.

Batiha GE, Al-Gareeb AI, Elekhnawy E, Al-Kuraishy HM. Potential role of lipoxin in the management of COVID-19: a narrative review. Inflammopharmacology. 2022 Sep 16:1-9.

Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE. Hemolytic anemia in COVID-19. Annals of Hematology. 2022 Jul 8:1-9.

Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Alruwaili M, AlRuwaili R, Albogami SM, Alorabi M, Saad HM, Simal-Gandara J. Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal. Inflammopharmacology. 2022 Nov 23:1-7.

Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GE. Nitazoxanide and COVID-19: a review. Molecular Biology Reports. 2022 Sep 12:1-8.

Alkhayyat SS, Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, AboKamer AM, Batiha GE, Simal-Gandara J. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail. Inflammation Research. 2022 Aug 8:1-9.

Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NA, Alexiou A, Batiha GE. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. International immunopharmacology. 2022 Jan 6:108516.

Batiha GE, Al-Gareeb AI, Rotimi D, Adeyemi OS, Al-Kuraishy HM. Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer. Scientific African. 2022 Oct 22:e01407.

Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Habotta OA, Batiha GE. High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology. 2022 Apr 26:1-0.

Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Alexiou A, Batiha GE. Calprotectin: The link between acute lung injury and gastrointestinal injury in Covid-19: Ban or boon. Current Protein and Peptide Science. 2022 May 1;23(5):310-20.

Al-Thomali AW, Al-Kuraishy HM, Al-Gareeb AI, K. Al-buhadiliy A, De Waard M, Sabatier JM, Khan Khalil AA, Saad HM, Batiha GE. Role of neuropilin 1 in COVID-19 patients with acute ischemic stroke. Biomedicines. 2022 Aug 20;10(8):2032.

Al-Kuraishy HM, Al-Gareeb AI, Batiha GE. The possible role of ursolic acid in Covid-19: a real game changer. Clinical Nutrition ESPEN. 2022 Feb 1;47:414-7.

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Central effects of ivermectin in alleviation of Covid-19-induced dysautonomia. Current Drug Targets. 2022 Oct 1;23(13):1277-87.

Al-Kuraishy HM, Al-Fakhrany OM, Elekhnawy E, Al-Gareeb AI, Alorabi M, De Waard M, Albogami SM, Batiha GE. Traditional herbs against COVID-19: back to old weapons to combat the new pandemic. European Journal of Medical Research. 2022 Dec;27(1):1-1.

Nadwa EH, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E, Albogami SM, Alorabi M, Batiha GE, De Waard M. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2022 Dec 3:1-6.

Al-Kuraishy HM, Al-Buhadily AK, Al-Gareeb AI, Alorabi M, Hadi Al-Harcan NA, El-Bouseary MM, Batiha GE. Citicoline and COVID-19: vis-à-vis conjectured. Naunyn-schmiedeberg’s Archives of Pharmacology. 2022 Sep 5:1-3.

Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE. An insight into the placental growth factor (PlGf)/angii axis in Covid-19: a detrimental intersection. Biotechnology and Genetic Engineering Reviews. 2022 Sep 15:1-20.

Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GE. Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail. Egyptian Journal of Medical Human Genetics. 2022 Dec;23(1):1-6.

Al-Kuraishy HM, Al-Gareeb AI, Al-Maiahy TJ, Alexiou A, Mukerjee N, Batiha GE. Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19. Biotechnology and Genetic Engineering Reviews. 2022 Sep 15:1-21.

Al-Kuraishy HM, Al-Gareeb AI, Albezrah NK, Bahaa HA, El-Bouseary MM, Alexiou A, Al-Ziyadi SH, Batiha GE. Pregnancy and COVID-19: high or low risk of vertical transmission. Clinical and Experimental Medicine. 2022 Oct 17:1-1.

Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of Post-COVID syndromes: a new perspective. Virology Journal. 2022 Dec;19(1):1-20.

Al‐Kuraishy HM, Al‐Gareeb AI, Mohammed AA, Alexiou A, Papadakis M, Batiha GE. The potential link between Covid‐19 and multiple myeloma: A new saga. Immunity, Inflammation and Disease. 2022 Dec;10(12):e701.

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A single or double-edged effect?. Current Protein and Peptide Science. 2022 May 1;23(5):321-34.

Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Aljowaie RM, Almutairi SM, Alexiou A, Batiha GE. The Prospective Effect of Allopurinol on the Oxidative Stress Index and Endothelial Dysfunction in Covid-19. Inflammation. 2022 Feb 24:1-7.

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Mukerjee N, Al-Hamash SM, Al-Maiahy TJ, Batiha GE. 5-HT/CGRP pathway and Sumatriptan role in Covid-19. Biotechnology and Genetic Engineering Reviews. 2022 Aug 31:1-26.

El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022 May 13:1-7.

Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Alexiou A, Batiha GE. Impact of Sitagliptin on Non-diabetic Covid-19 Patients. Current molecular pharmacology. 2022 Jul 1;15(4):683-92.

Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Jeandet P, Saad HM, Batiha GE. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19. Inflammopharmacology. 2022 Apr 29:1-1.

Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Welson NN, Batiha GE, Conte-Junior CA. Selinexor and COVID-19: The Neglected Warden. Frontiers in Pharmacology. 2022;13.

Al-Kuraishy HM, Al-Gareeb AI, Fageyinbo MS, Batiha GE. Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19. Future Science OA. 2022 Mar(0):FSO797.

Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM, Sonbol FI, Batiha GE. Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties. Clinical and Experimental Medicine. 2022 May 24:1-0.

Al-Kuraishy HM, Al-Gareeb AI, Albogami SM, Jean-Marc S, Nadwa EH, Hafiz AA, A. Negm W, Kamal M, Al-Jouboury M, Elekhnawy E, Batiha GE. Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19. Pharmaceuticals. 2022 Nov 7;15(11):1361.

Al-Kuraishy HM, Al-Gareeb AI, Onohuean H, El-Saber Batiha G. COVID-19 and erythrocrine function: The roller coaster and danger. International Journal of Immunopathology and Pharmacology. 2022 May 14;36:03946320221103151.

Al-Kuraishy HM, Al-Gareeb AI, Welson NN, Batiha GE. Trimetazidine and COVID-19-induced acute cardiac injury: a missed key. International Journal of Clinical Pharmacy. 2022 Apr 21:1-2.

Al-Kuraishy HM, Al-Gareeb AI, Al-Harcan NA, Alexiou A, Batiha GE. Tranexamic Acid and Plasminogen/Plasmin Glaring Paradox in COVID-19. Endocrine, Metabolic & Immune Disorders Drug Targets. 2022 Aug 1.

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Cannabinoids Receptors in COVID-19: Perpetrators and Victims. Current Medicinal Chemistry. 2022.

Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, Dubey R, Prabhakar PK, Batiha GE. COVID-19 and diabetes: will novel drugs for diabetes help in COVID-19?. Current Molecular Pharmacology. 2022 Sep 8.

Alomair BM, Al-Kuraishy HM, Al-Buhadily AK, Al-Gareeb AI, De Waard M, Elekhnawy E, Batiha GE. Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?. Inflammopharmacology. 2022 Sep 30:1-5.

Al‐kuraishy HM, Al‐Gareeb AI, Kaushik A, Kujawska M, Batiha GE. Ginkgo biloba in the management of the COVID‐19 severity. Archiv der Pharmazie. 2022:e2200188.

Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, Cavalu S, El-Bouseary MM, Sonbol FI, Batiha GE. Changes in the blood viscosity in patients with SARS-CoV-2 infection. Frontiers in medicine. 2022;9.

Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Youssef FS, El-Sherbeni SA, Negm WA. A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. Inflammopharmacology. 2022 Dec 9:1-1.

Batiha GE, Al-Gareeb AI, Qusti S, Alshammari EM, Kaushik D, Verma R, Al-Kuraishy HM. Deciphering the immunoboosting potential of macro and micronutrients in COVID support therapy. Environmental Science and Pollution Research. 2022 Apr 7:1-6.

Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022 May 13.

Alkazmi L, Al-Kuraishy HM, Batiha GE, Mostafa-Hedeab G, De Waard M, Sabatier JM, Kabrah SM, Saad HM, Al-Gareeb AI, Simal-Gandara J. Roxadustat for SARS-CoV-2 infection: old signaling raised new hopes. Drugs in R&D. 2022 Sep;22(3):183-6.

Al-Kuraishy HM, Al-Gareeb AI, Jalal NA, Kabrah SM, Alexiou A, Batiha GE. SARS-CoV-2 infection and C1-esterase inhibitor: camouflage pattern and new perspective. Current protein and peptide science. 2022 Jul 1;23(7):465-74.

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Batiha GE. Covid-19 and L-arginine supplementations: Yet to find the missed key. Current Protein & Peptide Science. 2022 May 12.

Al-kuraishy H, Al-Gareeb A, Cruz-Martins N, Batiha G. Tranexamic acid in COVID-19 pneumonia. Authorea Preprints. 2022 Mar 30.

Al-Kuraishy HM, Al-Gareeb AI, Rauf A, Alhumaydhi FA, Kujawska M. Mechanistic insight and possible mechanism of seizure in Covid-19: The nuances and focal points. CNS & Neurological Disorders Drug Targets. 2022 May 17.

Al-Kuraishy HM, Al-Gareeb AI, Bungau SG, Radu AF, Batiha GE. The potential molecular implications of adiponectin in the evolution of SARS-CoV-2: Inbuilt tendency. Journal of King Saud University-Science. 2022 Sep 30:102347.

Batiha GE, Wasef L, Teibo JO, Shaheen HM, Zakariya AM, Akinfe OA, Teibo TK, Al-Kuraishy HM, Al-Garbee AI, Alexiou A, Papadakis M. Commiphora myrrh: a phytochemical and pharmacological update. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2022 Nov 18:1-6.

Al-Kuraishy HM, Al-Gareeb AI, Eldahshan OA, Batiha GE. Oxytocin in diabetic Covid-19 patients: a new perspective. Natural Product Research. 2022 Sep 19:1-2.

Albogami SM, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Al-Gareeb AI, Alorabi M, Alotaibi SS, De Waard M, Sabatier JM, Saad HM, Batiha GE. Hypoxia-Inducible Factor 1 and Preeclampsia: A New Perspective. Current Hypertension Reports. 2022 Nov 7:1-6.

Alomair BM, Al-Kuraishy HM, Al-Gareeb AI, Al-Hamash SM, De Waard M, Sabatier JM, Saad HM, El-Saber Batiha G. Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals. 2022 Sep 14;15(9):1147.

Al-Kuraishy HM, Issa HK, Al-Gareeb AI, El-Bouseary MM, Youssef A, Abdelaziz AS, Khalifa HA, Batiha GE. The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument. Inflammopharmacology. 2022 Dec;30(6):2441-6.

Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier JM, Saad HM, Batiha GE. Statins use in alzheimer disease: bane or boon from frantic search and narrative review. Brain Sciences. 2022 Sep 24;12(10):1290.

Batiha GE, Moubarak M, Shaheen HM, Zakariya AM, Usman IM, Rauf A, Adhikari A, Dey A, Alexiou A, Hetta HF, Al-Gareeb AI. Favipiravir in SARS-CoV-2 infection: Is it Worthwhile?. Combinatorial Chemistry & High Throughput Screening. 2022 Apr 14.

Al-kuraishy HM, Al-Gareeb AI, Alkhuriji AF, Al-Megrin WA, Elekhnawy E, Negm WA, De Waard M, Batiha GE. Investigation of the impact of rosuvastatin and telmisartan in doxorubicin-induced acute cardiotoxicity. Biomedicine & Pharmacotherapy. 2022 Oct 1;154:113673.

Saad HM, Tourky GF, Al-kuraishy HM, Al-Gareeb AI, Khattab AM, Elmasry SA, Alsayegh AA, Hakami ZH, Alsulimani A, Sabatier JM, Eid MW. The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity. Diagnostics. 2022 Dec;12(12):2985.

Al-Hussaniy HA, Al-kuraishy AA, Jalil HJ. Evaluation of the efficacy of adrenergic neurons inhibition through various surgical and therapeutic regimens on controlling blood pressure and circadian rhythm in patients with uncontrolled hypertension. Journal of Clinical Trials and Experimental Investigations. 2022 Dec 14;1(3):106-13.

Alorabi M, Cavalu S, Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, Negm WA, Youssef A, El-Kadem AH, Saad HM, Batiha GE. Pentoxifylline and berberine mitigate diclofenac-induced acute nephrotoxicity in male rats via modulation of inflammation and oxidative stress. Biomedicine & Pharmacotherapy. 2022 Aug 1;152:113225.

Al-Kuraishy HM, Al-Gareeb AI, Alsayegh AA, Hakami ZH, Khamjan NA, Saad HM, Batiha GE, De Waard M. A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease. Neurochemical Research. 2022 Nov 21:1-22.

Al-Hussaniy HA, Al-Kuraishy HM, Abdulameer AG. The Use of Panax Ginseng to Reduce the Cardiotoxicity of Doxorubicin and Study its Effect on Modulating Oxidative Stress, Inflammatory, and Apoptosis Pathways. Open Access Macedonian Journal of Medical Sciences. 2022 Mar 20;10(A):715-9.

Batiha GE, Al-Kuraishy HM, Al-Maiahy TJ, Al-Buhadily AK, Saad HM, Al-Gareeb AI, Simal-Gandara J. Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship. Diabetology & Metabolic Syndrome. 2022 Dec;14(1):1-6.

Sami OM, Shams HA, Aziz HM, Al-kuraishy HM. The Substantial effects of statins therapy on PCSK9 and adipocytokine in dyslipidemic non-diabetic patients: prevailing motive. HIV Nursing. 2022 Oct 18;22(2):1434-9.